Maiwald is Gold Partner for the 2nd „Pharma and Biotech Patent Litigation North America“ conference

On 18 and 19 November, the second annual Pharma & Biotech Patent Litigation North America conference will take place at the Marriott Downtown in Philadelphia. Maiwald is proud to support this important event as a Gold Partner.

Dr Eva Ehlich will participate in a panel discussion. The topic is how life science companies deal with the increased risks under Section 112 following the Supreme Court’s decision in Amgen v. Sanofi. Together with the other panelists, she will discuss how patent applications can be made future-proof, how to respond to aggressive PGR challenges, and how strategies for prosecution and litigation can be adapted in light of stricter standards for enablement and written description.

This event brings together leading IP experts from the pharmaceutical and biotech industries. Current topics such as Hatch-Waxman and BPCIA proceedings, Section 112 enablement, the influence of the UPC on global strategies and legal issues surrounding AI inventions and the Inflation Reduction Act will be discussed. With over 50 speakers, including numerous in-house counsels, the event provides in-depth insights into litigation trends and features interactive roundtables and ample networking opportunities. The event aims to facilitate practical discussion on cross-border patent disputes and strategic IP protection.